Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 31;8(41):70431-70440.
doi: 10.18632/oncotarget.19712. eCollection 2017 Sep 19.

Natural Killer Cell Activity for IFN-gamma Production as a Supportive Diagnostic Marker for Gastric Cancer

Affiliations
Free PMC article

Natural Killer Cell Activity for IFN-gamma Production as a Supportive Diagnostic Marker for Gastric Cancer

Jongmi Lee et al. Oncotarget. .
Free PMC article

Abstract

Background/aim: Decreased Natural killer cell activity (NKA) for interferon-gamma production (NKA-IFNγ) has been reported in cancer patients. The aim of this study was to determine the diagnostic performance of NKA-IFNγ for gastric cancer (GC).

Results: NKA-IFNγ levels were decreased in 261 GC patients with all stages of tumor compared to those in 48 healthy donors (P < 0.001), and lower levels of NKA-IFNγ were associated with higher GC stages. NKA-IFNγ levels were also associated with clinicopathological parameters including tumor size, depth of invasion, and lymph node metastasis. NKA-INFγ assay had better diagnostic value (AUC = 0.822) compared to serum CEA (0.624) or CA19-9 assay (0.566) (P < 0.001). Using different cut-off levels, serum CEA and CA19-9 showed sensitivities of 6.1-14.2% and 4.2-28.0%, respectively, which were much lower than that of NKA-IFNγ (55.6-66.7%).

Methods: This study included 261 patients with newly diagnosed GC and 48 healthy donors. NKA for IFNγ was determined by enzyme immunoassay after incubation of whole blood, and diagnostic performance was evaluated.

Conclusions: NK cell activities for IFNγ production could be used as a supportive non-invasive tumor marker for GC diagnosis.

Keywords: diagnostic marker; gastric cancer; interferon-gamma; natural killer cell activity.

Conflict of interest statement

CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. NKA-IFNγ, CEA, and CA19-9 levels from healthy donors compared with that from gastric cancer patients
In box plots, central box represent the 25th to 75th centiles, the lines within the boxes represent the median and error bars represent 95% confidence interval for the medians.
Figure 2
Figure 2. NKA-IFNγ levels in healthy donors (white boxes) compared to those in gastric cancer patients (gray boxes) in different age groups (groups; ≤ 35 years, 36-45 years, 46-55 years, 56-65 years and 65< years)
(*P < 0.05; ** P < 0.001). In box plots, central box represent the 25th to 75th centiles, the lines within the boxes represent the median and error bars represent 95% confidence interval for the medians.
Figure 3
Figure 3. NKA-IFNγ levels in healthy donors and gastric cancer patients according to TNM stage (I-IV)
In box plots, central box represent the 25th to 75th centiles, the lines within the boxes represent the median and error bars represent 95% confidence interval for the medians.
Figure 4
Figure 4. ROC curves analysis of NKA-IFNγ, CEA, and CA19-9 assays to discriminate healthy donors from gastric cancer (GC) patients (A) and early GC patients (B)

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Lim D, Ha M, Song I. Trends in major cancer mortality in Korea, 1983-2012, with a joinpoint analysis. Cancer Epidemiol. 2015;39:939–946. - PubMed
    1. Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, Yan C. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev. 2014;15:6295–6300. - PubMed
    1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–49. - PMC - PubMed
    1. Rocca YS, Roberti MP, Julia EP, Pampena MB, Bruno L, Rivero S, Huertas E, Sanchez Loria F, Pairola A, Caignard A, Mordoh J, Levy EM. Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15. Front Immunol. 2016;7:413. - PMC - PubMed
    1. Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med. 1998;105:27S–34S. - PubMed
Feedback